OncologyTimes_KingSpread_21x14.0.1.inddThe following is a press release from Caris Life Sciences about a breakthrough presentation of data at the recent American Society for Clinical Oncology (ASCO) meeting. In this study, the median overall survival was eight years longer in ovarian and fallopian tube cancer patients treated using Caris Molecular Intelligence profiling vs. those who did not. In a subset of patients who recurred, using this technology patients lived two and a half years longer. The details are summarized in the release as follows:

Continue Reading…